Christian Henry Buys Shares of Ginkgo Bioworks

Christian Henry made a significant move by purchasing 25,000 shares of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) on June 11, 2026. This insider transaction did not involve a pre-planned trading plan and reflects Henry's confidence in the company's future.

Other Institutional Activity in Ginkgo Bioworks

BlackRock, Inc. grew its holdings by 68,978 shares, ending with 3,642,347 shares worth about $22.3 million. Meanwhile, Viking Global Investors LP held steady with 3,577,128 shares valued at $21.9 million. Baillie Gifford & Co also maintained its position with 2,391,649 shares valued at approximately $14.7 million. Erste Asset Management GmbH trimmed its stake by 52,272 shares, resulting in 1,947,728 shares worth $10.7 million. Vanguard Capital Management LLC established a new position with 1,914,428 shares valued at $11.7 million.

Ginkgo Bioworks Holdings, Inc. Stock Up 13.4%

Shares of Ginkgo Bioworks traded near $7.89. The company has a market cap of $515.4 million and a beta of 1.8. Over the past 52 weeks, the stock has seen a low of $5.37 and a high of $17.58. The 50-day moving average is $8.20, while the 200-day moving average stands at $9.45. The company has a strong current ratio of 5.15 and a quick ratio of 4.95, although its debt-to-equity ratio is relatively high at 92.68.

Recent Earnings

Ginkgo Bioworks reported $151.4 million in revenue, although it experienced a revenue decline of 49.1%. The company has a negative net margin of 201.1% and a return on equity of -56%. The next earnings release is scheduled for August 6, 2026.

Insider Buying and Selling at Ginkgo Bioworks Holdings, Inc.

On June 11, 2026, several insiders, including Christian Henry, Ross Fubini, Sri Kosuri, and Harry Sloan, each bought 25,000 shares. These transactions were not part of any pre-arranged plans. On May 22, 2026, Steven Coen sold 307 shares at an average price of $8.33, while on May 21, 2026, he bought 743 shares.

Analysts Set New Price Targets

On March 12, 2026, BTIG maintained a sell rating with a $5.00 price target. Earlier, on January 8, 2026, TD Cowen maintained a buy rating with a $12.00 price target. The consensus among analysts gives Ginkgo Bioworks an average target price of $8.50 based on two opinions.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc. is a biotechnology company based in Boston, Massachusetts. Founded in 2008, it specializes in developing a platform for cell engineering. The company operates through its Cell Engineering and Biosecurity segments, providing solutions in areas like functional genomics and bioinformatics. Ginkgo serves industries including pharmaceuticals, agriculture, and defense, with Dr. Jason Kelly as its CEO.

Bottom Line

Christian Henry's recent purchase of Ginkgo Bioworks shares signals a potential vote of confidence in the company's prospects. The biotech firm, with its innovative cell engineering platform, continues to attract institutional interest despite challenges reflected in its recent earnings. Keep in mind that insider transactions are disclosed after they occur and may not indicate current positions.